Form 4: Vanda Pharmaceuticals CEO Sells Shares to Cover Tax Obligations

Vanda Pharmaceuticals' CEO, Mihael Hristos Polymeropoulos, sold shares of common stock to cover tax obligations related to the vesting of Restricted Stock Units (RSUs).

Summary

• Mihael Hristos Polymeropoulos, the President and CEO of Vanda Pharmaceuticals, sold shares of the company's common stock on March 4th and 5th, 2024.
• The sales were executed to satisfy tax obligations related to the acquisition of shares from the settlement of vested RSUs.
• On March 4th, 30,884 shares were sold at a weighted average price of $4.2438, with prices ranging from $4.22 to $4.275.
• On March 5th, 24,288 shares were sold at a weighted average price of $4.1285, with prices ranging from $4.12 to $4.14.
• Following these transactions, Polymeropoulos directly owns 1,871,730 shares of Vanda Pharmaceuticals' common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing simply reports the sale of shares for tax purposes, which is a routine transaction. There is no indication of positive or negative sentiment towards the company's prospects.

Industry Context

Sales of shares by company executives are a common occurrence, often related to tax obligations or diversification of personal holdings. The impact on the stock price is usually minimal unless the sale is substantial or indicative of a negative outlook.

Stakeholder Impact

• The sale of shares by the CEO could have a minor impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale.

Key Dates